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Abstract
Background: Pyronaridine, a Mannich base anti-malarial with high efficacy against drug resistant
Plasmodium falciparum, is currently evaluated as a fixed dose combination with artesunate for the
treatment of uncomplicated malaria. In this study, the in vitro activity of pyronaridine against clinical
isolates of P. falciparum from Lambaréné, Gabon, was assessed in order to obtain baseline data on
its activity prior to its future use in routine therapy. Moreover, follow-up assessment on the in vitro
activity of chloroquine, artesunate and quinine was performed.
Methods: In vitro response of field isolates of P. falciparum to pyronaridine, chloroquine, artesunate
and quinine was assessed using the traditional WHO microtest. In addition, the histidine-rich
protein 2 (HRP-2) assay was performed and evaluated for its future implementation for follow-up
of drug susceptibility testing.
Results: Pyronaridine exhibited a high in vitro activity against P. falciparum, with a geometric mean
cut-off concentration of 9.3 nmol/l. Fifty percent effective concentrations were 1.9 nmol/l and 2.0
nmol/l in the WHO microtest and HRP-2 assay, respectively. Results matched closely in vivo findings
from a recent clinical trial on pyronaridine-artesunate treatment. One isolate showed diminished
sensitivity to artesunate. For chloroquine and quinine resistance levels were comparable to prior
studies from Lambaréné. Results from the novel HRP-2 assay corresponded well to those obtained
by the WHO microtest.
Conclusion: Pyronaridine is highly active in chloroquine-resistant parasites and seems a promising
partner drug for artemisinin-based combination therapy in Africa.
Background
Malaria continues to be a major cause of morbidity and
mortality in sub-Saharan Africa, particularly in young
children. Early detection and effective chemotherapy
remain the cornerstones in its control [1]. The rapid devel-
opment and spread of anti-malarial drug resistance has
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made surveillance of drug sensitivity a high priority issue.
In addition to assessing the activity of common anti-
malarials against Plasmodium falciparum in routine sur-
veys, the evaluation of new compounds against field iso-
lates is of major importance for drug development.
In Lambaréné, Gabon, routine anti-malarial drug suscep-
tibility monitoring has been performed since 1992 [2-5].
So far the WHO microtest – one of the longest used and
best validated assays for the assessment of in vitro drug
sensitivity under field conditions – has been used for this
purpose [6]. Meanwhile, novel methods in drug suscepti-
bility testing have been developed, such as the histidine-
rich protein II (HRP-2) assay [7]. This method, based on
HRP-2 measurement in an enzyme-linked immunosorb-
ent assay (ELISA), is equally simple to implement, but
considerably less labour intensive compared with the
WHO microtest. Due to these advantages, the WHO
microtest will be replaced for standard drug susceptibility
monitoring in Lambaréné in the future by the novel HRP-
2 assay. Previous findings from laboratory adapted clones
and from different geographical regions suggest that
results obtained by the HRP-2 assay be comparable with
those obtained by the WHO microtest [7].
The anti-malarial agent pyronaridine is a Mannich base
derivative of mepacrine, one of the earliest synthetic anti-
malarials [8]. It is currently evaluated as a fixed dose com-
bination with artesunate for the treatment of uncompli-
cated falciparum and vivax malaria in adult and paediatric
patients [9]. Its anti-plasmodial activity involves interfer-
ence with the glutathione-dependent detoxification of
haem and targeting of β-haematin formation [10].
Reports from paediatric patients in Africa showed that
pyronaridine is effective against chloroquine resistant
strains of P. falciparum in vivo [9,11], yet data from South-
East Asia indicate the potential for rapid development of
resistance against pyronaridine, when used as mono-
therapy [12].
The present study aimed to assess the susceptibility of
clinical P. falciparum field isolates from Lambaréné to pyr-
onaridine in order to obtain baseline data on the activity
of this for Africa yet novel anti-malarial drug prior to its
widespread use in routine therapy. In addition the study
was designed to assess the potential for the novel HRP-2
assay to replace the standard WHO microtest.
Methods
Study area and patients
The study was carried out at the Medical Research Unit of
the Albert Schweitzer Hospital in Lambaréné, Gabon, in a
region of stable, hyperendemic P. falciparum malaria
transmission [13,14]. Patients attending the outpatient
clinic between March and October 2006 were asked to
participate in the study if they met the following inclusion
criteria: P. falciparum monoinfection with 1,000–100,000
asexual parasites per μl blood, no schizontaemia, no signs
or symptoms of severe malaria, and no history of intake of
anti-malarial drugs in the preceding month. Information
about age, sex, and duration of fever was collected on a
questionnaire. Informed consent was obtained from par-
ticipants or their legal representatives. The study was
approved by the Ethics Committee of the International
Foundation for the Albert Schweitzer Hospital in Lam-
baréné.
In vitro drug sensitivity assays
Two different methods of drug sensitivity testing were
deployed in order to assess the susceptibility of fresh field
isolates of P. falciparum to pyronaridine, artesunate, chlo-
roquine and quinine. First, the standard World Health
Organization in vitro microtest was used similar to previ-
ous reports, measuring drug-dependent inhibition of sch-
izont maturation (SMI) within 24 hours by microscopic
assessment [2-5]. Briefly, two millilitres of venous blood
were mixed with complete parasite culture medium
(RPMI 1640, 200 μM hypoxanthine, 25 mM Hepes, 0.5%
albumax, 2 mM l-glutamine) to a final concentration of
5% blood medium mixture (BMM). Ninety-six-well test
plates were pre-dosed in ascending quantities of drugs,
dosing each plate with all respective drugs for one isolate.
Final drug concentrations were 0.5–365.9 nmol/l BMM
for pyronaridine (Mr: 910.04), 0.1–85.8 nmol/l BMM for
artesunate (Mr: 384.425), 0.8–51.2 μmol/l blood for
chloroquine (Mr: 515.867) and 55–3567 nmol/l BMM
for quinine (Mr: 785.06). Artesunate, chloroquine and
quinine were dissolved in 70% ethanol, pyronaridine was
resuspended in distilled water. In accordance to the proto-
cols distributed by the World Health Organization drug
concentrations for chloroquine are expressed as related to
blood due to their considerable accumulation in erythro-
cytes [6].
Fifty μl BMM were transferred into scheduled wells and
incubated at 37.5°C in candle jars. After 24 hours para-
sites were harvested and Giemsa-stained thick blood films
were prepared. The number of mature schizonts was
microscopically counted against 200 asexual parasites in
each well. Tests were considered successful if at least 10%
schizont maturation was observed in the drug-free con-
trol-well.
In addition, the HRP-2 assay was performed according to
the published standard operational procedures [7]. Two
ml of venous blood were mixed with parasite medium to
a concentration of 3% BMM. Test plates were pre-dosed to
the same final concentrations as in the WHO test and
incubated for 72 hours at 37°C in candle jars. To test for
successful in vitro parasite-growth, a thick blood smear ofMalaria Journal 2009, 8:79 http://www.malariajournal.com/content/8/1/79
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one control-well was performed after 26 h. One non-
treated 26 h sample was frozen to calculate background
HRP-2 production. Parasite culture was judged successful
if at least 10% parasites matured to schizonts at the 26-
hour time point. After 72 h plates were freeze-thawed
twice. Parasite growth, calculated from HRP-2 levels, was
measured with an enzyme linked immunosorbent assay at
an absorbent maximum of 450 nm.
Statistical analysis
Non-linear regression analysis with 4-parameter fits of
log-concentration/response curves was used to determine
individual inhibitory concentrations of the respective iso-
lates. All regressions were checked manually. Cut off con-
centrations were calculated as geometric mean of the
lowest individual concentrations with no mature schizont
among 200 parasites in the WHO microtest. Nonparamet-
ric analysis was used for concentration data that was not
normally distributed. A two-tailed Mann-Whitney-U-Test
was performed in order to test for difference between the
two drug sensitivity assays. All tests were performed at a
two sided significance level of α = 0.05.
Results
Ninety-five outpatients attending the Albert Schweitzer
Hospital were included in this study. The patients' median
age was three years, ranging from three month to 18 years,
and 55% were female. Median asexual parasitaemia at
presentation was 36,500 per μl blood. In the schizont
maturation microtest 32, 36, 34, and 32 out of 95 isolates
yielded valid results for pyronaridine, chloroquine,
artesunate and quinine, respectively. Twenty-five isolates
fulfilled the criteria for successful parasite-culture in the
HRP-2 assay and 15, 16, 12 and 14 were successfully
employed for drug sensitivity testing, respectively. Post-
hoc analysis of the unexpected low success rate of cultiva-
tion, especially in the HRP-2 assay, revealed that poor
growth was associated with one lot of the commercially
acquired medium. Those isolates were identified and
excluded from the analysis. Table 1 shows 50 percent, 99
percent and cut-off concentrations of the tested drugs as
obtained by the WHO microtest and HRP-2 assay.
Pyronaridine
Pyronaridine inhibited in vitro growth and schizont matu-
ration in the WHO assay at a geometric mean cut-off con-
centration of 9.3 nmol/l BMM. The respective geometric
mean EC99 concentration in the HRP-2 assay was 9.0
nmol/l. In one isolate schizont maturation was observed
at a pyronaridine concentration of 122 nmol/l BMM,
resulting in a cut-off concentration of 366 nmol/l BMM.
Further two isolates showed cut-off concentrations of 122
nmol/l. Geometric mean EC50 values were 1.9 and 2.0
nmol/l BMM for the WHO microtest and the HRP-2 assay,
respectively.
Chloroquine
The geometric mean cut-off concentration for chloro-
quine was 21.7 μmol/l blood in the WHO assay, 19.2
μmol/l blood was the respective EC99 value in the HRP-2
assay. The most sensitive isolate showed a cut-off concen-
tration of 3.2 μmol/l blood, all other isolated exhibited
cut-off concentrations of 6.4 μmol/l blood or higher. In
four parasite cultures, microscopic assessment revealed
schizont maturation up to the highest concentration of
51.3 μmol/l blood. The 50 percent effective concentra-
tions were 7.1 μmol/l blood in the WHO microtest and
5.5 μmol/l in the HRP-2 assay, respectively.
Artesunate
Fifty percent effective concentrations were 2.1 nmol/l
BMM in the microtest and 2.3 nmol/l BMM in the HRP-2
assay for artesunate. Two isolates exhibited schizont mat-
uration at 28.6 nmol/l BMM, yielding cut-off concentra-
tions of 85 nmol/l BMM. In one isolate in vitro schizont
maturation was not inhibited by the highest artesunate
concentration of 85 nmol/l BMM. The same isolate exhib-
ited good sensitivity to pyronaridine and to quinine. The
geometric mean cut-off concentration was 9.2 nmol/l
Table 1: EC50, EC99 and cut-off concentrations of pyronaridine, chloroquine, artesunate and quinine in WHO microtest and HRP-2 
assay
WHO Microtest HRP-2 assay
N EC50 (95%CI) Cut-off concentration (95%CI) N EC50 (95% CI) EC99 (95%CI)
Pyronaridine 32 1.87
(1.40–2.48)
9.32
(5.2–13.9)
15 2.03
(1.57–2.63)
9.03
(6.42–12.69)
Chloroquine 36 7.1
(5.2–9.6)
21.7
(15.4–30.6)
16 5.5
(4.4–6.9)
19.2
(15.3–24.2)
Artesunate 34 2.08
(1.48–2.92)
9.24
(6.53–13.06)
12 2.25
(1.70–2.99)
15.24
(10.45–22.24)
Quinine 32 272
(210–353)
873
(723–1053)
14 204
(167–250)
662
(561–781)
All values are in nmol/l BMM except for chloroquine (μmol/l blood),
Means and 95% confidence intervals are depicted as antilog of arithmetic mean of log-transformed dataMalaria Journal 2009, 8:79 http://www.malariajournal.com/content/8/1/79
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BMM. The HRP-2 assay showed a mean EC99 level of 15.2
nmol/l BMM.
Quinine
All isolates were susceptible to quinine. Highest cut-off
concentrations were at 1783 nmol/l BMM, thus well
below the threshold of resistance (5120 nmol/l BMM).
The geometric mean cut-off concentration was 873 nmol/
l, the EC99 in the HRP-2 assay was 662 nmol/l BMM. The
EC50 values in the WHO microtest and in the HRP-2 assay
were 272 and 204 nmol/l BMM, respectively.
Activity correlation of the tested drugs
Correlation analysis of EC50 values of the individual iso-
lates was performed in order to assess the relationship
between sensitivity of parasites to pyronaridine, chloro-
quine, artesunate and quinine (Table 2). Significant corre-
lation was found between in vitro activities of the anti-
malarials quinine and chloroquine (r = 0.50, p < 0.005).
Interestingly, the activity of pyronaridine was correlated
with artesunate (r = 0.84 p < 0.0001), but not with chlo-
roquine or quinine.
Comparison of HRP-2 assay and WHO microtest
No statistically significant differences between the EC50
values from the two drug sensitivity assays were found in
U-test of pooled data of the individual drugs (p = 0.82 for
pyronaridine, 0.72 for artesunate, 0.11 for chloroquine
and 0.20 for quinine). Differences in geometric means of
EC50 values were largest for chloroquine (7.1 μmol/l, 95%
CI 5.2–9.6 in the WHO microtest versus 5.5 μmol/l 95%
CI: 4.4–6.9 in the HRP-2 assay, p = 0.11) and quinine
(272 nmol/l 95% CI: 210–353 versus 204 nmol/l 95%CI
167–250, respectively. p = 0.20). Figure 1 shows the dis-
tribution of EC50 values for the respective drugs.
Cut-off concentrations as determined by the WHO micro-
test correlate closely to the equivalent EC99 values of the
HRP-2 assay (Table 1). Significantly more isolates yielded
valid results in the microtest (36%) than in the HRP-2
based assay (15%) (p < 0.001).
Discussion
Pyronaridine exhibited a high level of in vitro activity
against isolates of P. falciparum from infected Gabonese
subjects in this study. Fifty percent effective concentra-
tions were 2.0 and 1.9 nmol/l, which is consistent with
previously published data from studies with laboratory
strains and field isolates obtained by a different drug sen-
sitivity assay (isotopic hypoxanthine assay) [15,16].
Median pyronaridine concentrations of 9.3 nmol/l (EC99
in HRP-2 assay) and 9.0 nmol/l (cut-off concentration in
WHO microtest) inhibited growth of P. falciparum in vitro.
In a recent pharmacokinetic assessment of a fixed-dose
pyronaridine artesunate combination in African children,
the mean maximal plasma concentrations of pyronarid-
ine were 115 nmol/l in patients [9]. Earliest reappearances
of parasites in peripheral blood in this study were
observed on day 21 (one patient) and day 28 (three
patients) after treatment. Interestingly, the patient with
parasite reappearance on day 21 exhibited a pyronaridine
plasma level of 9.9 nmol/l at that time. In polynomial
regression analysis of pooled plasma levels of all patients,
mean pyronaridine blood concentrations fell below levels
of 9 nmol/l on day 22. First reappearances in vivo therefore
occurred only after plasma levels fell below concentra-
tions similar to cut-off concentrations obtained in this in
vitro study.
Although the extrapolation of in vitro drug sensitivity
assessments to in vivo data should always be cautious [17],
in vitro results of the present study matched closely clinical
findings of this clinical trial on pyronaridine-artesunate
combination therapy.
The relationship between in vitro activity of pyronaridine
and chloroquine against P. falciparum has been discussed
controversially in previous reports and contradictory con-
clusions concerning cross-resistance have been drawn
from studies, which found a significant correlation
between pyronaridine and chloroquine in vitro activity
and differences in activity of pyronaridine against chloro-
quine resistant and sensitive strains [15,16,18,19]. In the
present study, in vitro response to chloroquine was poor in
all tested isolates, yet parasites proved to be highly suscep-
tible to pyronaridine. There was no statistically significant
correlation of the in vitro activities of the two drugs against
P. falciparum. These in vitro findings and the recently
reported high cure rates of three days pyronaridine-artesu-
nate combination therapy provide convincing evidence
against a clinically significant cross resistance of pyronar-
idine and chloroquine in vivo. The results underline the
usefulness of pyronaridine for the treatment of patients in
Table 2: Activity correlation between pyronaridine, chloroquine, 
artesunate and quinine in fresh Plasmodium falciparum isolates
Pyronaridine Chloroquine Artesunate
Chloroquine R2 0.13 --
P 0.52
N3 0
Artesunate R2 0.84 -0.07 -
P <.0001* 0.69
N2 9 3 0
Quinine R2 0.06 0.50 0.02
P 0.74 0.0037* 0.93
N3 0 3 1 3 0
R2: correlation coefficient in pairwise correlation analysis
* statistically significantMalaria Journal 2009, 8:79 http://www.malariajournal.com/content/8/1/79
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regions affected by P. falciparum resistant to chloroquine
[9,11].
Since the first in vitro drug susceptibility assessment in
Lambaréné in 1992 [2], high levels of resistance against
chloroquine have been observed in vitro and in vivo [3-5].
Similar to previous studies in vitro response to chloro-
quine was poor in this study. EC50 levels were comparable
to the last assessment in 2002 [5], despite a decrease in
drug pressure due to a change of national treatment poli-
cies to artemisinin-based combination therapy in 2003.
Artesunate was highly active against P. falciparum in the
present assessment. EC50 levels were similar to recent in
vitro and in vivo findings at the study site and in neigh-
bouring countries [20-22]. One isolate showed a dimin-
ished sensitivity to artesunate with schizont maturation
up to the highest concentration of 85.8 nmol/l and a cor-
responding EC50 level of 19.9 nmol/l. Another isolate had
a comparably high EC50 value of 10.1 nmol/l and a respec-
tive cut-off concentration in the WHO microtest of 85.8
nmol/l. These findings support recent in vitro susceptibil-
ity assessments by Cojean et al [23], reporting on 6 out of
397 African P. falciparum isolates with dihydroartemisinin
EC50 levels above 10 nmol/l and a maximum EC50 of 31.8
nmol/l in one isolate. Especially in the light of increasing
availability and use of artemisinins in many parts of
Africa, the importance of close surveillance for susceptibil-
ity as well as strict deployment of artemisinins exclusively
in combination therapy with effective partner drugs can-
not be overemphasized.
As in previous reports from Lambaréné, susceptibility to
quinine was high in this study. Mean EC50 (204 and 272
nmol/l in HRP-2 assay and WHO microtest, respectively)
were comparable to results obtained in 2002 (286 nmol/
l) [5]. Despite its widespread use, quinine remains a
highly effective anti-malarial in Gabon, especially as drug
of choice for parenteral treatment of hospitalized patients.
Comparative assessment of the HRP-2 assay and WHO
microtest was performed in order to establish baseline
data for the use of the ELISA based assay in Lambaréné in
the future. Results obtained by the HRP-2 assay closely
paralleled those obtained by the WHO microtest despite
methodological problems in this study due to a deficient
batch of culture medium. Considering its reduced labour-
intensity and good reproducibility the HRP-2 assay can,
therefore, be recommended for follow up of anti-malarial
drug susceptibility testing and will replace the WHO
microtest in future assessments at our study site.
Conclusion
Artesunate, chloroquine and quinine in vitro drug activity
was similar, compared to data from earlier in vitro assess-
ments, and results of the HRP-2 assay were comparable to
those obtained by the traditional WHO microtest.
Box plots of pyronaridine, chloroquine, artesunate and quinine EC50 in HRP-2 assay and WHO microtest Figure 1
Box plots of pyronaridine, chloroquine, artesunate and quinine EC50 in HRP-2 assay and WHO microtest.Publish with BioMed Central    and   every 
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The study demonstrated high anti-malarial activity of pyr-
onaridine against fresh field isolates of P. falciparum and
corresponded well to recent findings of pyronaridine anti-
malarial activity in vivo. Pyronaridine is recommended for
further clinical development in combination therapy and
continued in vitro drug activity monitoring.
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